Apex Biotechnology Corp. (TPE:1733)

Market Cap	3.07B
Revenue (ttm)	2.03B
Net Income (ttm)	162.25M
Shares Out	99.95M
EPS (ttm)	1.61
PE Ratio	19.11
Forward PE	4.40
Dividend	1.20 (3.87%)
Ex-Dividend Date	Jun 11, 2025

Volume	269,438
Average Volume	233,694
Open	31.05
Previous Close	31.00
Day's Range	30.45 - 31.15
52-Week Range	26.40 - 35.05
Beta	0.26
RSI	66.72
Earnings Date	Aug 8, 2025

About Apex Biotechnology

Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemosmart gold hemoglobin screening systems. It also provides pesticide residue check systems; and care management and tele-health services. The company was incorporated in 1997 and is headquartered in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1733

Financial Performance

In 2024, Apex Biotechnology's revenue was 1.85 billion, an increase of 10.48% compared to the previous year's 1.68 billion. Earnings were 128.00 million, an increase of 10.55%.